BioSpace News Archive

As states begin to re-open, 40 percent of Americans still view going to the hospital as a risky behavior – even more than going to the hair salon, a concert or the beach, according to a new national survey released tod

ENHERTU ® Achieved a Tumor Response Rate of 45.3% in Patients with HER2 Positive Metastatic Colorectal Cancer in Phase 2 DESTINY-CRC01 Trial

Patients Receiving QINLOCK for Fourth-line GIST Reported Improved Quality of Life and Better Physical and Role Functioning Compared with a Decline in Placebo

Data reinforce potential of FCR001 to induce long-lasting immune tolerance to donated organ

Detailed results from the positive registrational, randomized controlled Phase II DESTINY-Gastric01 trial showed AstraZeneca and Daiichi Sankyo Company, Limited’s (Daiichi Sankyo) ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in objective response rate (ORR) and overall survival (OS),

Peer-reviewed publication in Alzheimer’s & Dementia: Translational Research & Clinical Interventions validates potential of drug discovery platform and ability to study early stages of disease pathology

Poster Presentation at American Society of Clinical Oncology (ASCO) Annual Meeting Highlights TPX-0046 Potent Inhibition of Wildtype RET and RET Mutations

Mixology Clothing Company, one of the Tri-State area’s premier contemporary fashion specialty retailer, today announced that it has selected the BIOPROTECTUs™ System by ViaClean Technologies to disinfect and protect all of its retail locations in Manhattan, Westchester, New Jersey and Long Island.

- First Presentation of Clinical Data for CX-2029, a Probody Drug Conjugate, Directed Against CD71: A Previously Undruggable Target - - Data Updates for CX-2009 Support Phase 2 Investigations in Breast Cancer - - Favorable Tolerability Profile Demonstrated for Anti-PD-L1 and Anti-CTLA-4 Probody Therapeutics - - Company to Host Webcast Today, -

Data are featured as an ASCO poster presentation and will be part of the Sarcoma Highlights Session on Sunday, May 31, 2020 at 3:30pm ET